Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Marc Casper reported the sale of 5,000 common shares of TMO. The filing shows a sale dated
Brokerage details list Fidelity Brokerage Services LLC and the transaction type is listed as Cash. The filing is a Form 144 disclosure of insider sales under the issuer symbol TMO.
Filer submitted a Form 144 notice to sell Common stock of the issuer (symbol TMO). The filing lists multiple restricted stock vesting lots and share counts by vesting date, including 980 shares vesting 02/23/2024, 955 shares vesting 02/28/2024, and other lots of 776, 705, 577, 434, 389, 233, 123, and 52 shares on various dates. The listed broker is Fidelity Brokerage Services LLC.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported two tax-withholding dispositions of common stock on February 28, 2026. He delivered 3,473.759 shares and 1,211.168 shares at $521.11 per share to cover tax liabilities, rather than executing open-market sales. Following these dispositions, he directly held 123,925.358 common shares. Additional common shares are held indirectly by the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported two tax-withholding share dispositions. She transferred 262.6700 and 85.4090 shares of common stock at
Thermo Fisher Scientific executive Joseph R. Holmes, VP & Chief Accounting Officer, reported several small dispositions of common stock on February 28, 2026. The transactions used code F, meaning shares were withheld to cover tax liabilities rather than sold in open-market trades. Blocks of stock were withheld at
Thermo Fisher Scientific Executive Vice President Michel Lagarde reported two tax-withholding dispositions of common stock. On February 28, 2026, he delivered 836.8800 shares and 359.7250 shares of Thermo Fisher common stock at $521.1100 per share to cover tax obligations.
Thermo Fisher Scientific President & COO Gianluca Pettiti reported two tax-withholding dispositions of common stock under a Form 4. On February 28, 2026, he surrendered 741.7100 and 331.6810 shares at $521.11 per share to cover tax obligations, and directly owned 25,450.8320 shares afterward.
Thermo Fisher Scientific executive Stephen Williamson reported tax-related share dispositions. On
After these transactions, Williamson held 32,499.4000 shares of Common Stock directly. He also reported 12,674.0000 shares held indirectly "By SLAT," with a footnote stating he disclaims beneficial ownership of indirectly owned securities except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported three Form 4 transactions on common stock. He disposed of approximately 816 shares through tax-withholding dispositions at a reported price of $521.11 per share to satisfy tax obligations. After these transactions, he directly owns about 22,557 shares of Thermo Fisher Scientific common stock.